2023 World Conference on Lung Cancer (Posters)-EP13.06. Radiotheranostics targeting Delta-Like Ligand 3 Expressing Small-Cell Lung Cancers.

EP13.06. Radiotheranostics targeting Delta-Like Ligand 3 Expressing Small-Cell Lung Cancers. - PDF(Slides)

Pdf Summary

Researchers conducted a study to develop targeted therapy for small cell lung cancer (SCLC) by focusing on Delta-Like Ligand 3 (DLL3) expression. The study involved screening and assessing 100 humanized antibodies to determine their binding affinities and other properties. Two leading candidates, mAb1 and mAb2, were found to be promising in both imaging and therapy studies. The antibodies were labeled with radioactive isotopes for imaging (immunoPET) and therapeutic purposes. In vivo imaging using immunoPET showed high levels of tumor uptake with low background in non-tumor organs. Biodistribution analysis confirmed these findings. The therapy studies demonstrated durable tumor responses and improved therapeutic efficacy compared to control groups. Overall survival was prolonged for mice treated with the experimental arms. Some transient hematologic suppression was observed, but blood cell counts normalized within a few weeks. The study suggests that DLL3-directed radioimmunoconjugates have the potential to serve as diagnostic tracers, prognostic biomarkers, and therapeutic agents for SCLC patients. The research was supported by various foundations and organizations. The findings highlight the promise of these novel radiotheranostics in improving the clinical outcomes of SCLC patients.

Asset Subtitle

Salomon Tendler

Meta Tag

Speaker Salomon Tendler

Topic SCLC & Neuroendocrine Tumors: Preclinical

Keywords

targeted therapy

small cell lung cancer

DLL3 expression

humanized antibodies

immunoPET

therapeutic efficacy

overall survival

radioimmunoconjugates

diagnostic tracers

clinical outcomes